Post-effective Amendment to an S-8 Filing (s-8 Pos)
January 13 2017 - 05:11PM
Edgar (US Regulatory)
As filed with the Securities and Exchange Commission on January 13, 2017
Registration No. 333-92424
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1 TO
Form S-8 Registration Statement No. 333-92424
Form S-8 Registration Statement No. 333-138325
UNDER
THE
SECURITIES ACT OF 1933
AMGEN INC.
(Exact name
of registrant as specified in its charter)
|
|
|
Delaware
|
|
95-3540776
|
(State of Incorporation)
|
|
(I.R.S. Employer
Identification No.)
|
One Amgen Center Drive
Thousand Oaks, California 91320-1799
(805) 447-1000
(Address
of principal executive offices, including zip code)
Amgen Inc. Amended and Restated 1999 Equity Incentive Plan (f/k/a the Immunex
Corporation 1999 Stock Option Plan)
Amgen Inc. Amended and Restated Assumed Avidia Equity Incentive Plan (f/k/a the Avidia, Inc.
Amended and Restated 2003 Equity Incentive Plan
(Full title of the plan)
Jonathan P. Graham, Esq.
Senior Vice President, General Counsel
and Secretary
One Amgen
Center Drive
Thousand Oaks, California 91320-1799
(805) 447-1000
(Name,
address, including zip code, and telephone number, including area code, of agent for service)
Indicate by
check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and
smaller reporting company in Rule 12b-2 of the Exchange Act (Check one):
|
|
|
|
|
|
|
Large Accelerated filer
|
|
☒
|
|
Accelerated filer
|
|
☐
|
|
|
|
|
Non-Accelerated filer
|
|
☐ (Do not check if a smaller reporting company)
|
|
Smaller reporting company
|
|
☐
|
EXPLANATORY NOTE / DEREGISTRATION OF UNSOLD SECURITIES
Amgen Inc. (the Company) previously registered shares of the Companys common stock, $0.0001 par value per share, under the
following registration statements (the Registration Statements) concerning shares issuable under certain employee benefit and equity plans and agreements. The Company is filing these post-effective amendments to the Registration
Statements (Post-Effective Amendments) in order to deregister any securities registered and unsold under the Registration Statements and to terminate the Registration Statements. The approximate number of unsold shares is set forth below
with respect to each Registration Statement. The shares are being removed from registration and the Registration Statements are being terminated because the plans referenced below have now expired or been terminated and all shares that were issuable
under the plans have been issued.
|
|
|
|
|
|
|
|
|
|
|
|
|
Registration
No.
|
|
Date Filed
With the
SEC
|
|
Name of Equity Plan or Agreement
|
|
Number of Shares
Originally
Registered
|
|
|
Approximate
Number of
Shares
Deregistered
Hereby
|
|
|
|
|
|
|
333-92424
|
|
7/16/2002
10/30/2002
|
|
Amgen Inc. Amended and Restated 1999 Equity Incentive Plan
(f/k/a the Immunex Corporation 1999 Stock Option Plan) Amendment No. 1
|
|
|
19,274,402
less 550 shares
deregistered by
Amendment No. 1
Total:
19,273,852
|
|
|
|
7,235,326
|
|
|
|
|
|
|
333-138325
|
|
10/31/2006
|
|
Amgen Inc. Amended and Restated Assumed Avidia Equity Incentive Plan (f/k/a the Avidia, Inc. Amended and Restated 2003 Equity Incentive Plan)
|
|
|
266,276
|
|
|
|
87,172
|
|
SIGNATURES
In accordance with the requirements of the Securities Act of 1933, as amended, the registrant, Amgen Inc., certifies that it has reasonable
grounds to believe that it meets all of the requirements for filing these Post-Effective Amendments and has duly caused and authorized the officers whose signatures appear below to sign these Post-Effective Amendments on its behalf by the
undersigned, in the City of Thousand Oaks, State of California, on the 13
th
day of January, 2017.
|
|
|
AMGEN INC.
|
|
|
By:
|
|
/s/ Robert A. Bradway
|
Robert A. Bradway
|
Chairman of the Board, Chief Executive Officer and President
|
POWER OF ATTORNEY
Each person whose signature appears below hereby authorizes and appoints Robert A. Bradway, David W. Meline and Jonathan P. Graham as
attorneys-in-fact and agents, each acting alone, with full powers of substitution to sign on his behalf, individually and in the capacities stated below, and to file any and all amendments (including these Post-Effective Amendments filed herewith)
to the Registration Statements listed herein above, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting to those attorneys-in-fact and agents full power
and authority to perform any other act on behalf of the undersigned required to be done.
Pursuant to the requirements of the Securities
Act of 1933, these Post-Effective Amendments have been signed by the following persons in the capacities and on the dates indicated.
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
/s/ Robert A. Bradway
Robert A. Bradway
|
|
Chairman of the Board, Chief Executive Officer and President
(Principal Executive Officer)
|
|
January 13, 2017
|
|
|
|
/s/ David W. Meline
David W. Meline
|
|
Chief Financial Officer
(Principal Financial Officer)
|
|
January 13, 2017
|
|
|
|
/s/ Annette L. Such
Annette L. Such
|
|
Vice President, Finance and Chief Accounting Officer
(Principal Accounting Officer)
|
|
January 13, 2017
|
|
|
|
/s/ David Baltimore
David Baltimore
|
|
Director
|
|
January 13, 2017
|
|
|
|
/s/ Frank J. Biondi, Jr.
Frank J. Biondi, Jr.
|
|
Director
|
|
January 13, 2017
|
|
|
|
/s/ François de Carbonnel
François de Carbonnel
|
|
Director
|
|
January 13, 2017
|
|
|
|
|
|
|
|
|
/s/ Robert A. Eckert
Robert A. Eckert
|
|
Director
|
|
January 13, 2017
|
|
|
|
/s/ Greg C. Garland
Greg C. Garland
|
|
Director
|
|
January 13, 2017
|
|
|
|
/s/ Fred Hassan
Fred Hassan
|
|
Director
|
|
January 13, 2017
|
|
|
|
/s/ Rebecca M. Henderson
Rebecca M. Henderson
|
|
Director
|
|
January 13, 2017
|
|
|
|
/s/ Frank C. Herringer
Frank C. Herringer
|
|
Director
|
|
January 13, 2017
|
|
|
|
/s/ Tyler Jacks
Tyler Jacks
|
|
Director
|
|
January 13, 2017
|
|
|
|
/s/ Ellen J. Kullman
Ellen J. Kullman
|
|
Director
|
|
January 13, 2017
|
|
|
|
/s/ Judith C. Pelham
Judith C. Pelham
|
|
Director
|
|
January 13, 2017
|
|
|
|
/s/ Ronald D. Sugar
Ronald D. Sugar
|
|
Director
|
|
January 13, 2017
|
|
|
|
/s/ R. Sanders Williams
R. Sanders Williams
|
|
Director
|
|
January 13, 2017
|
EXHIBIT INDEX
|
|
|
Exhibit
Number
|
|
Description
|
|
|
24.1
|
|
Power of Attorney (included on signature page)
|
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2023 to Mar 2024